NO20034944D0 - Re-aktiverte T-celler for adoptiv immunoterapi - Google Patents

Re-aktiverte T-celler for adoptiv immunoterapi

Info

Publication number
NO20034944D0
NO20034944D0 NO20034944A NO20034944A NO20034944D0 NO 20034944 D0 NO20034944 D0 NO 20034944D0 NO 20034944 A NO20034944 A NO 20034944A NO 20034944 A NO20034944 A NO 20034944A NO 20034944 D0 NO20034944 D0 NO 20034944D0
Authority
NO
Norway
Prior art keywords
activated
cells
adoptive immunotherapy
adoptive
immunotherapy
Prior art date
Application number
NO20034944A
Other languages
English (en)
Inventor
Micheal L Gruenberg
Surendra Chavan
Original Assignee
Valeocyte Therapies Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valeocyte Therapies Llc filed Critical Valeocyte Therapies Llc
Publication of NO20034944D0 publication Critical patent/NO20034944D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO20034944A 2002-03-07 2003-11-06 Re-aktiverte T-celler for adoptiv immunoterapi NO20034944D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/094,667 US20030175272A1 (en) 2002-03-07 2002-03-07 Re-activated T-cells for adoptive immunotherapy
PCT/US2002/029520 WO2003077658A1 (en) 2002-03-07 2002-09-17 Re-activated t-cells for adoptive immunotherapy

Publications (1)

Publication Number Publication Date
NO20034944D0 true NO20034944D0 (no) 2003-11-06

Family

ID=27788151

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20034944A NO20034944D0 (no) 2002-03-07 2003-11-06 Re-aktiverte T-celler for adoptiv immunoterapi

Country Status (7)

Country Link
US (1) US20030175272A1 (no)
EP (1) EP1480519A1 (no)
AU (1) AU2002341697A1 (no)
BR (1) BR0209494A (no)
NO (1) NO20034944D0 (no)
WO (1) WO2003077658A1 (no)
ZA (1) ZA200309435B (no)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030235908A1 (en) * 2000-02-24 2003-12-25 Xcyte Therapies, Inc. Activation and expansion of cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7572631B2 (en) * 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US20030119185A1 (en) * 2000-02-24 2003-06-26 Xcyte Therapies, Inc. Activation and expansion of cells
US6797514B2 (en) * 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
AU779289B2 (en) * 2000-05-25 2005-01-13 Xcyte Therapies, Inc. Methods for restoring or enhancing T-cell immune surveillance following naturally or artifically induced immunosuppression
AU2002341717A1 (en) * 2001-09-17 2003-04-01 Medcell Biologics, Llc. Cell therapy system
US20030170238A1 (en) * 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US20050084967A1 (en) 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
US20040175373A1 (en) * 2002-06-28 2004-09-09 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
JP2006524991A (ja) * 2003-05-08 2006-11-09 エクサイト セラピーズ インコーポレーティッド 抗原特異的ｔ細胞の作製および単離の方法
CA2539716A1 (en) * 2003-09-22 2005-04-07 Xcyte Therapies, Inc. Compositions and methods to accelerate hematologic recovery
LT2573166T (lt) * 2004-02-26 2016-09-26 Immunovative Therapies, Ltd. T ląstelių paruošimo būdas ląstelių terapijai
US7592431B2 (en) * 2004-02-26 2009-09-22 Immunovative Therapies, Ltd. Biodegradable T-cell Activation device
US8865224B2 (en) 2004-10-14 2014-10-21 Immunovative Therapies Ltd. Allogeneic cellular immunotherapy for opportunistic infection
ES2531142T3 (es) 2005-10-17 2015-03-11 Sloan Kettering Inst Cancer Péptidos WT1 de unión a HLA de clase II, y composiciones y métodos que los comprenden
CA2645766A1 (en) 2006-04-10 2007-10-25 Sloan Kettering Institute For Cancer Research Immunogenic wt-1 peptides and methods of use thereof
EP2471901A4 (en) * 2009-08-25 2013-06-26 Takara Bio Inc PROCESS FOR PRODUCING T-CELL POPULATION IN THE PRESENCE OF RETINOIC ACID
KR102121492B1 (ko) 2011-05-03 2020-06-11 이뮤노베이티브 테라피스, 엘티디. 면역치료를 사용하는 il-12의 유도
KR102202460B1 (ko) 2011-05-03 2021-01-14 이뮤노베이티브 테라피스, 엘티디. 생세포를 포함하는 생물학적 약물을 처리하기 위한 방법
RU2011130448A (ru) * 2011-07-22 2013-01-27 Зао "Евроген" Методы и наборы для увеличения разнообразия т-клеток
JP6282598B2 (ja) 2012-01-13 2018-02-21 メモリアル スローン ケタリング キャンサー センター 免疫原性ｗｔ１ペプチド及びその使用方法
HUE052541T2 (hu) 2013-01-15 2021-05-28 Memorial Sloan Kettering Cancer Center Immunogén WT-1 peptidek és eljárások azok alkalmazására
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
US11046782B2 (en) 2016-03-30 2021-06-29 Musc Foundation For Research Development Methods for treatment and diagnosis of cancer by targeting glycoprotein A repetitions predominant (GARP) and for providing effective immunotherapy alone or in combination
MX2020008327A (es) 2018-02-09 2020-10-28 Immatics Us Inc Metodos para preparar celulas t.
DE102018108996B4 (de) 2018-02-09 2021-10-21 Immatics US, Inc. Verfahren zur Herstellung autologer T-Zellen

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US31253A (en) * 1861-01-29 Machine
US53361A (en) * 1866-03-20 Improved apparatus for desiccating eggs
US19048A (en) * 1858-01-05 Hbnky sanders
US3821087A (en) * 1972-05-18 1974-06-28 Dedrick R Cell culture on semi-permeable tubular membranes
US3883393A (en) * 1972-05-18 1975-05-13 Us Health Education & Welfare Cell culture on semi-permeable tubular membranes
US3997396A (en) * 1973-07-02 1976-12-14 Monsanto Company Method for the in vitro propagation and maintenance of cells
US4087327A (en) * 1976-04-12 1978-05-02 Monsanto Company Mammalion cell culture process
US4206015A (en) * 1977-11-11 1980-06-03 United States Of America Method of simulation of lymphatic drainage utilizing a dual circuit, woven artificial capillary bundle
US4200689A (en) * 1977-11-11 1980-04-29 United States Of America Method of cell culture using a dual circuit, woven artificial capillary bundle
US4220725A (en) * 1978-04-03 1980-09-02 United States Of America Capillary cell culture device
JPS5642584A (en) * 1979-09-18 1981-04-20 Asahi Chem Ind Co Ltd Cell cultivation method
US4301249A (en) * 1980-07-23 1981-11-17 Merck & Co., Inc. High titer production of hepatitis A virus
US5192537A (en) * 1984-03-30 1993-03-09 Cellcor Inc. Method of treating renal cell carcinoma using activated mononuclear cells, renal tumor antigen and cimetidine
US5766920A (en) * 1982-08-11 1998-06-16 Cellcor, Inc. Ex vivo activation of immune cells
US4546083A (en) * 1983-04-22 1985-10-08 Stolle Research & Development Corporation Method and device for cell culture growth
US4804628A (en) * 1984-10-09 1989-02-14 Endotronics, Inc. Hollow fiber cell culture device and method of operation
US4629685A (en) * 1984-11-16 1986-12-16 Ciba-Geigy Corporation Process for irradiating polyimides
US4937071A (en) * 1985-04-23 1990-06-26 New York University Method for augmenting immune response
US4690915A (en) * 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US5081029A (en) * 1985-09-25 1992-01-14 Oncogen Methods of adoptive immunotherapy for treatment of aids
US4722902A (en) * 1985-11-04 1988-02-02 Endotronics, Inc. Apparatus and method for culturing cells, removing waste and concentrating product
US5002879A (en) * 1986-05-06 1991-03-26 Merrell Dow Pharmaceuticals Treatment of tumors with autologous LAK cells, interleukin-2 and an ornithine decarboxylase inhibitor
US4894342A (en) * 1986-05-12 1990-01-16 C. D. Medical, Inc. Bioreactor system
US4849329A (en) * 1986-05-30 1989-07-18 E. I. Du Pont De Nemours And Company Process for preparing lymphokine activated killer cells
US4971795A (en) * 1986-07-08 1990-11-20 Biomira, Inc. Enhancement of the cellular immune response using carbohydrate primed DTH effector cells expressing the CD5+/CD8- phenotype
AU7873187A (en) * 1986-08-08 1988-02-24 University Of Minnesota Method of culturing leukocytes
US4861589A (en) * 1987-03-23 1989-08-29 Trustees Of Boston University Method for therapeutically treating abnormal cells expressing a major histocompatibility complex class II antigen using cytolytic inducer T4 cells
US4808151A (en) * 1987-04-27 1989-02-28 E. I. Du Pont De Nemours And Company Simplified method for the preparation of human lymphokine activated killer cells
US5399347A (en) * 1987-06-24 1995-03-21 Autoimmune, Inc. Method of treating rheumatoid arthritis with type II collagen
US5041289A (en) * 1987-11-13 1991-08-20 Becton Dickinson And Company Method of purging residual tumor cells in vitro with lymphokine activated cytotoxic cells
US5057423A (en) * 1987-12-18 1991-10-15 University Of Pittsburgh Method for the preparation of pure LAK-active lymphocytes
US5015585A (en) * 1988-02-23 1991-05-14 Robinson James R Method and apparatus for culturing and diffusively oxygenating cells on isotropic membranes
US5123901A (en) * 1988-02-25 1992-06-23 Carew E Bayne Method for separating pathogenic or toxic agents from a body fluid and return to body
US4999298A (en) * 1988-04-27 1991-03-12 W. R. Grace & Co.-Conn. Hollow fiber bioreactor culture system and method
US4973558A (en) * 1988-04-28 1990-11-27 Endotronics, Inc. Method of culturing cells using highly gas saturated media
US5858358A (en) * 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6534055B1 (en) * 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) * 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
FR2640638B1 (fr) * 1988-12-20 1991-02-15 Commissariat Energie Atomique Bioreacteur et dispositif pour la culture de cellules animales
US5242687A (en) * 1989-03-15 1993-09-07 Tkb Associates Limited Partnership Method of reducing cellular immune response involving T-cells using CD8-bearing antigen presenting cells
US5162225A (en) * 1989-03-17 1992-11-10 The Dow Chemical Company Growth of cells in hollow fibers in an agitated vessel
US6093872A (en) * 1989-05-05 2000-07-25 Systemix, Inc. Extended human hematopoiesis in a heterologous host
US5399346A (en) * 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5605822A (en) * 1989-06-15 1997-02-25 The Regents Of The University Of Michigan Methods, compositions and devices for growing human hematopoietic cells
US5763266A (en) * 1989-06-15 1998-06-09 The Regents Of The University Of Michigan Methods, compositions and devices for maintaining and growing human stem and/or hematopoietics cells
US5635386A (en) * 1989-06-15 1997-06-03 The Regents Of The University Of Michigan Methods for regulating the specific lineages of cells produced in a human hematopoietic cell culture
US5437994A (en) * 1989-06-15 1995-08-01 Regents Of The University Of Michigan Method for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells
US5728388A (en) * 1989-10-03 1998-03-17 Terman; David S. Method of cancer treatment
US5326763A (en) * 1989-10-12 1994-07-05 Allergan, Inc. Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US5123238A (en) * 1990-02-09 1992-06-23 Nut Research Company Of Australia Pty Limited Harvester
US5656421A (en) * 1990-02-15 1997-08-12 Unisyn Technologies, Inc. Multi-bioreactor hollow fiber cell propagation system and method
US5147289A (en) * 1990-03-29 1992-09-15 Therakos, Inc Non-specific immune system enhancement
US5061620A (en) * 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5147784A (en) * 1990-04-12 1992-09-15 Systemix, Inc. T-lymphocyte progenitor cell assay
US5635387A (en) * 1990-04-23 1997-06-03 Cellpro, Inc. Methods and device for culturing human hematopoietic cells and their precursors
EP0481058B1 (en) * 1990-05-03 1996-07-17 Systemix, Inc. Human lymphoid tissue in an immunocompromised host
US5229115A (en) * 1990-07-26 1993-07-20 Immunex Corporation Adoptive immunotherapy with interleukin-7
US5470730A (en) * 1990-09-28 1995-11-28 Immunex Method for producing TH -independent cytotoxic T lymphocytes
US5202254A (en) * 1990-10-11 1993-04-13 Endotronics, Inc. Process for improving mass transfer in a membrane bioreactor and providing a more homogeneous culture environment
US5374549A (en) * 1991-01-31 1994-12-20 Terumo Corporation Process of enriching adherent CD4+ T cells from monocyte depleted peripheral blood mononuclear cells with interleukin 2 and interleukin 4
US5206008A (en) * 1991-04-15 1993-04-27 Virginia Commonwealth University Enhancement of immune response
US6129916A (en) * 1991-04-19 2000-10-10 Tanox, Inc. Method of Increasing activation on proliferation of T cells using antibody-microbead conjugates
US5872222A (en) * 1991-04-19 1999-02-16 Tanox Biosystems, Inc. Conjugates of polymers and antibodies specific for T lymphocytes, and their use as adjuvants
US5637481A (en) * 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
IE922233A1 (en) * 1991-07-10 1993-01-13 Augusto C Ochoa Short-term anti-cd3 stimulation of lymphocytes to increase¹their in vivo activity
US6204058B1 (en) * 1992-02-07 2001-03-20 Vasogen Ireland Limited Treatment of autoimmune diseases
DK0633929T3 (da) * 1992-04-01 2004-06-28 Univ Rockefeller Fremgangsmåde til in vitro proliferation af dendritcelleforstadier og deres anvendelse til at producere immunogener
US5814295A (en) * 1992-04-10 1998-09-29 The Ohio State University Research Foundation Determination of lymph nodes enriched in tumor reactive cells their proliferation and their use in adoptive cellular therapy
US5466572A (en) * 1992-09-03 1995-11-14 Systemix, Inc. High speed flow cytometric separation of viable cells
WO1994023760A1 (en) * 1993-04-14 1994-10-27 The United States Of America As Represented By The Secretary Of The Navy Transgenic animal model for autoimmune diseases
DE69430315T2 (de) * 1993-08-06 2002-11-21 Epimmune Inc Methoden zur (ex vivo) therapie mittels peptid - bestueckten antigen - praesentierenden zellen zur aktivierung von ctl
US5409813A (en) * 1993-09-30 1995-04-25 Systemix, Inc. Method for mammalian cell separation from a mixture of cell populations
US5599705A (en) * 1993-11-16 1997-02-04 Cameron; Robert B. In vitro method for producing differentiated universally compatible mature human blood cells
US5622857A (en) * 1995-08-08 1997-04-22 Genespan Corporation High performance cell culture bioreactor and method
US5512444A (en) * 1994-03-01 1996-04-30 Ludwig Institute For Cancer Research Method for determining bladder tumors by assaying for MAGE-1,2,3 or 4
US5498537A (en) * 1994-03-09 1996-03-12 Cellco, Inc. Serum-free production of packaged viral vector
US5662813A (en) * 1994-10-21 1997-09-02 Bioseparations, Inc. Method for separation of nucleated fetal erythrocytes from maternal blood samples
US6461867B1 (en) * 1995-03-08 2002-10-08 The Scripps Research Institute Synthetic antigen presenting matrix
US5728581A (en) * 1995-06-07 1998-03-17 Systemix, Inc. Method of expanding hematopoietic stem cells, reagents and bioreactors for use therein
EP0852618A1 (en) * 1995-07-25 1998-07-15 Celltherapy Inc. Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease
US5627070A (en) * 1995-07-26 1997-05-06 Celltherapy, Inc. Cell growing device for in vitro cell population expansion
US5753506A (en) * 1996-05-23 1998-05-19 Cns Stem Cell Technology, Inc. Isolation propagation and directed differentiation of stem cells from embryonic and adult central nervous system of mammals
CA2278847A1 (en) * 1997-01-31 1998-08-06 Hemosol Inc. Method for the production of selected lymphocytes
CA2321199A1 (en) * 1998-02-19 1999-08-26 William A. Brady Compositions and methods for regulating lymphocyte activation
AU2002341717A1 (en) * 2001-09-17 2003-04-01 Medcell Biologics, Llc. Cell therapy system

Also Published As

Publication number Publication date
AU2002341697A1 (en) 2003-09-29
US20030175272A1 (en) 2003-09-18
WO2003077658A1 (en) 2003-09-25
BR0209494A (pt) 2005-08-23
EP1480519A1 (en) 2004-12-01
ZA200309435B (en) 2006-05-31

Similar Documents

Publication Publication Date Title
NO20034944D0 (no) Re-aktiverte T-celler for adoptiv immunoterapi
AU2003272582A8 (en) Re-activated t-cells for adoptive immunotherapy
CY2016009I2 (el) Ενωσεις για την αναστολη του ενζυμου πρωτεασωματος
DE60302032D1 (de) Künstliche Bandscheibe
DE602005036752T8 (de) Künstliche Bandscheibe
DE60330151D1 (de) Brennstoffzellensystem
DE60316596D1 (de) Brennstoffzellensystem
DK1835923T3 (da) Skemaer til intra-artikulær visco-supplering
DE10347121A8 (de) Ladegerät
DK1733039T3 (da) Forbedret bakteriel værtscelle til direkte ekspression af peptider
IS8570A (is) Stoðfrumulaus framhaldsrækt stofnfrumna
DE602004022088D1 (de) Zellkultivierungskolben
DE60331474D1 (de) Brennstoffzellensystem
DE60331959D1 (de) Brennstoffzellensystem
DE60322351D1 (de) Reaktionszelle
DK1539597T3 (da) Læsseliste
DE60332334D1 (de) Silikon enthaltende phenyl amidderivate verwendbar als mikrobiozide
AU2003272598A1 (en) Th1 cell adoptive immunotherapy
DE60312367D1 (de) Brennstoffzellensystem
DE502004008433D1 (de) Wägezelle
DK1482971T3 (da) Strategi til retroviral immunoterapi
FI20020607A (fi) Kantoaineen hionta
ATE516919T1 (de) Schleifscheibe
DE10303750B8 (de) Ausgleichsscheibenträger
NO20021482D0 (no) Föringsinnretning for plateelementer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application